OSENI TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ALOGLIPTIN (ALOGLIPTIN BENZOATE); PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)

Prieinama:

TAKEDA CANADA INC

ATC kodas:

A10BD09

INN (Tarptautinis Pavadinimas):

PIOGLITAZONE AND ALOGLIPTIN

Dozė:

25MG; 15MG

Vaisto forma:

TABLET

Sudėtis:

ALOGLIPTIN (ALOGLIPTIN BENZOATE) 25MG; PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30

Recepto tipas:

Prescription

Gydymo sritis:

DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0255250004; AHFS:

Autorizacija statusas:

CANCELLED PRE MARKET

Leidimo data:

2018-01-19

Prekės savybės

_OSENI_
_TM_
_ Product Monograph _
_Page 1 of 51_
PRODUCT MONOGRAPH
Pr
OSENI™
alogliptin (as alogliptin benzoate) and pioglitazone (as pioglitazone
hydrochloride)
12.5 mg/15 mg, 12.5 mg/30 mg, 12.5 mg/45 mg, 25 mg/15 mg, 25 mg/30 mg
and 25 mg/45 mg
tablets
Oral Antihyperglycemic Agent
DPP-4 Inhibitor + Thiazolidinedione
Incretin Enhancer
Takeda Canada Inc.
Oakville, Ontario L6M 4X8
Date of Preparation:
January 16, 2014
SUBMISSION CONTROL NO: 156813
_OSENI_
_TM_
_ Product Monograph _
_Page 2 of 51_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
............................................................25
STORAGE AND STABILITY
..........................................................................................32
SPECIAL HANDLING INSTRUCTIONS
.......................................................................32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................32
PART II: SCIENTIFIC INFORMATION
...............................................................................